Amgen presents TOWER study data at ASH Annual Meeting
Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »
Amgen presented data from its Phase 3 TOWER study at the 58th Annual Meeting and Exposition of the American Society of Hematology this week in San Diego. Read More »
AbbVie's risankizumab has been granted Orphan Drug Designation by the U.S. Food and Drug Administration for the investigational treatment of pediatric patients who have Crohn’s disease. Read More »
Naloxone has been made available without the need for a prescription in all Walgreens pharmacy locations in the Louisiana. Read More »
Amgen will partner with Janssen Biotech to assess the drug combination made up of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen, over the course of multiple clinical trials for the treatment of patients who have multiple myeloma. Read More »
Baxter International recently presented data regarding the SHARESOURCE remote patient management platform and the AMIA automated peritoneal dialysis system and their roles in more efficient home dialysis while supporting patients and their ability to be independent. Read More »
Baxter International recently presented its research on extracorporeal blood purification and its role in the removing of molecules associated with inflammation at the American Society of Nephrology’s annual Kidney Week. Read More »
Kmart Pharmacy has added Medicare Part D and its members can now use Kmart Pharmacy for their pharmaceutical needs in 2017 as their preferred provider. Read More »
Amgen's addition of RepathaA (evolocumab) to optimized statin therapy has resulted in a noteworthy statistical decrease of atherosclerosis in patients who have coronary artery disease. Read More »
Bristol-Myers Squibb and Innate Pharma have released the interim effectiveness analysis of its Phase 1/2 trial involving the lirilumab and Opdivo combination. Read More »
Amgen plans to partner with Janssen Biotech to further assess the drug combination of KYPROLIS, developed by Amgen, and DARZALEX, developed by Janssen. Read More »
McKesson Specialty Health hosted its two-day 2016 Onmark Fall Leadership Summit in Orlando, Florida, featuring the possible transformation that community oncology practices are having to make so they can survive in the ever-evolving world of care based on value and payment reform. Read More »
Walgreens Boots Alliance Inc. was recently honored by the American Ireland Fund at the 32nd Annual Chicago Dinner by awarding it with the American Ireland Fund Corporate Social Responsibility Award. Read More »
Jordan Howard, the leading rusher for the Chicago Bears, attended the 2016 Pulmonary Fibrosis Foundation’s volunteer meeting where he dedicated himself to fighting pulmonary fibrosis. Read More »
The National Pharmaceutical Council Board of Directors has appointed Dr. Joshua Ofman as its new vice chairman. Read More »
AbbVie's oral poly polymerase inhibitor valiparib has been granted Orphan Drug Designation by the U.S. Food and Drug Administration. Read More »
Amgen's results of its Phase 3 coronary intravascular imaging trial, call GLAGOV, will be presented at the American Heart Association Scientific Sessions 2016. Read More »
The Female Health Co.'s transformational merger with Aspen Park Pharmaceuticals has been finalized with both sides agreeing to modified terms. Read More »
Astellas USA Foundation has announced that it has appointed Moyra Knight its new president, replacing Jeffrey Winton in the position. Read More »
Astellas Pharma and Pfizer's joint-supplemental New Drug Application that will see the update of the XTANDI capsules product label has been approved by the Food and Drug Administration. Read More »
Amgen's Phase 3 clinical trial to assess XGEVA compared to zoledronic acid has achieved its primary goal of proving to delay the time to the first skeletal-related event on-study for multiple myeloma patients. Read More »